Physician profile
Robert Wertheimer
NPI 1972692598
$3,531.75
in general payments reported to CMS, 2019-2025
25 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $117 · 2021: $404 · 2022: $265 · 2023: $673 · 2024: $646 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $410.16 | 2022-2025 | Clareon, Argos, Tryptyr |
| Glaukos Corporation | $350.78 | 2019-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $327.90 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $324.01 | 2021-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Bausch & Lomb Americas INC. | $259.92 | 2022-2025 | Envista Mx60 Iol, Infuse, Miebo |
| Sun Pharmaceutical Industries INC. | $239.99 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $234.33 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Biotissue Holdings INC. | $204.07 | 2023-2025 | |
| Abbvie INC. | $181.45 | 2023-2025 | Durysta |
| Allergan, INC. | $154.80 | 2020-2022 | |
| Ocular Therapeutix, INC. | $124.60 | 2021-2025 | Dextenza |
| Dompe US, INC. | $121.98 | 2022-2023 | Oxervate |
| Oyster Point Pharma, INC. | $104.12 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $100.24 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $68.55 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $48.01 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $43.82 | 2025 | |
| Shire North American Group INC | $43.17 | 2019 | |
| Amgen INC. | $32.81 | 2025 | Tepezza |
| Harrow Eye, LLC | $31.59 | 2024 | Vevye |
| Sight Sciences, INC. | $31.51 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $28.70 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.34 | 2021 | |
| Coopervision INC. | $18.59 | 2025 | Misight Contact Lens |
| Visioneering Technologies, INC. | $18.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wertheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.